<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02988817</url>
  </required_header>
  <id_info>
    <org_study_id>GCT1021-01</org_study_id>
    <nct_id>NCT02988817</nct_id>
  </id_info>
  <brief_title>HuMax-AXL-ADC Safety Study in Patients With Solid Tumors</brief_title>
  <official_title>First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of Axl-specific Antibody-drug Conjugate (HuMax®-AXL-ADC) in Patients With Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genmab</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genmab</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the trial is to determine the maximum tolerated dose and to establish the
      safety profile of HuMax-AXL-ADC in a mixed population of patients with specified solid tumors
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial consists of two parts; a dose escalation part (phase I, first in- human (FIH)) and
      an expansion part (phase IIa).

      The dose escalation part has two dose escalation arms: the first arm investigates a once
      every 3 weeks (1Q3W) dosing schedule and the second arm investigates a three administrations
      over 4 weeks (3Q4W) dosing schedule.

      The Expansion part of the trial will further explore the recommended phase 2 dose and dosing
      regimens of HuMax-AXL-ADC as determined in Part 1
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2016</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Limiting Toxicities (DLTs)</measure>
    <time_frame>Dose Limiting Toxicities will be assessed from first treatment cycle (3 or 4 weeks)</time_frame>
    <description>As this is a phase I trial the main objective is to assess the recommended phase 2 dose of HuMax-AXL-ADC</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events (AEs)</measure>
    <time_frame>At end of trial (up to 24 months)</time_frame>
    <description>As this is a phase I trial the main objective is to assess the safety and tolerability of HuMax-AXL-ADC throughout the treatment periods of the patients participating in the trial.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) parameters, Cmax</measure>
    <time_frame>At end of trial (up to 10 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-tumor activity measured by tumor shrinkage (based on computerized tomography [CT]-scan evaluations), change in Cancer Antigen (CA) 125.</measure>
    <time_frame>At end of trial (up to 12 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) parameters, AUC</measure>
    <time_frame>At end of trial (up to 10 months)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">292</enrollment>
  <condition>Ovarian Cancer</condition>
  <condition>Cervical Cancer</condition>
  <condition>Endometrial Cancer</condition>
  <condition>Non Small Cell Lung Cancer</condition>
  <condition>Thyroid Cancer</condition>
  <condition>Melanoma</condition>
  <condition>Sarcoma</condition>
  <arm_group>
    <arm_group_label>HuMax-AXL-ADC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All arms of the trial (both in escalation and expansion phase) will be administered HuMax-AXL-ADC</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HuMax-AXL-ADC</intervention_name>
    <description>All arms of the trial (both in escalation and expansion phase) will be administered (HuMax-AXL-ADC)</description>
    <arm_group_label>HuMax-AXL-ADC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. For the dose escalation part: Patients with selected, relapsed solid tumors who have
             failed available standard therapy or who are not candidates for standard therapy.

          2. For the expansion part: Patients with relapsed, advanced and/or metastatic solid
             tumors who are not candidates for standard therapy

          3. Patients must have measurable disease according to Response Evaluation Criteria In
             Solid Tumors (RECIST).

          4. For the expansion patients must provide a fresh tumor biopsy at enrolment

          5. Age ≥ 18 years.

          6. Acceptable renal function

          7. Acceptable liver function

          8. Acceptable hematological status

          9. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

         10. Life expectancy of at least three months.

         11. Patients, both females and males, of childbearing/reproductive potential must agree to
             use adequate contraception while included in the trial and for six months after the
             last infusion of HuMax-AXL-ADC

         12. Patients must provide a signed informed consent form before any trial relates
             activities are carried out.

        Exclusion Criteria:

          1. Acute deep vein thrombosis or clinically relevant pulmonary embolism, not stable for
             at least 4 weeks prior to first IMP administration.

          2. Have clinically significant cardiac disease

          3. Known congestive heart failure and/ or a known decreased cardiac ejection fraction of
             &lt; 45%. A baseline QT interval as corrected by Fridericia's formula (QTcF) &gt; 480 msec,
             a complete left bundle branch block (defined as a QRS interval ≥ 120 msec in left
             bundle branch block form) or an incomplete left bundle branch block.

          4. Uncontrolled hypertension

          5. Have received granulocyte colony stimulating factor (G-CSF) or granulocyte/macrophage
             colony stimulating factor support 3 weeks prior to first IMP administration.

          6. Have received a cumulative dose of corticosteroid ≥ 150 mg prednisone (or equivalent
             doses of corticosteroids) within two weeks before the first Investigational Medicinal
             Product (IMP) administration.

          7. History of ≥ grade 3 allergic reactions to monoclonal antibody therapy as well as
             known or suspected allergy or intolerance to any agent given in the course of this
             trial.

          8. Major surgery within four weeks before first IMP administration.

          9. Any history of intracerebral arteriovenous malformation, cerebral aneurysm, brain
             metastases or stroke.

         10. Any anticancer therapy including; small molecules, immunotherapy, chemotherapy
             monoclonal antibodies or any other experimental drug within five half-lives but
             maximum four weeks before first infusion. Accepted exceptions are bisphosphonates,
             denosumab and gonadotropin-releasing hormone agonist or antagonist.

         11. Prior therapy with a conjugated or unconjugated auristatin derivative/vinca-binding
             site targeting payload.

         12. Radiotherapy within 14 days prior to first IMP administration.

         13. Known past or current malignancy other than inclusion diagnosis, except for:

               -  Cervical carcinoma of Stage 1B or less.

               -  Non-invasive basal cell or squamous cell skin carcinoma.

               -  Non-invasive, superficial bladder cancer.

               -  Prostate cancer with a current PSA level &lt; 0.1 ng/mL.

               -  Breast cancer in BRCA1 or BRCA2 positive ovarian cancer patients.

               -  Any curable cancer with a complete response (CR) of &gt; 2 years duration.

         14. Melanoma patients with an LDH ≥ 3 x ULN.

         15. Ongoing significant, uncontrolled medical condition including:

             o Serious, non-healing wound, skin ulcer (of any grade), or bone fracture.

         16. Grade 2 or higher peripheral neuropathy.

         17. Clinically significant active viral, bacterial or fungal infection

         18. Known human immunodeficiency virus seropositivity.

         19. Known positive serology for hepatitis B (unless due to vaccination or passive
             immunization due to immunoglobulin therapy)

         20. Known positive serology for hepatitis C (unless due to immunoglobulin therapy)

         21. Substance abuse, medical, psychological or social conditions that may interfere with
             the patient's participation in the trial or evaluation of the trial result

         22. History of organ allograft (except for corneal transplant) or autologous or allogeneic
             bone marrow transplant, or stem cell rescue within 3 months prior to the first dose of
             IMP

         23. Body weight &lt; 40 kg

         24. Women who are pregnant or breast feeding.

         25. Pulmonary hemorrhage or hemoptysis &gt; 2.5 ml blood within 6 weeks unless cause has been
             addressed and is medically resolved.

         26. History of acute pneumonitis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ignace Vergote, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitair Ziekenhuizen Leuven</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mika Bohlbro</last_name>
    <phone>+45 3377 9569</phone>
    <email>m.bohlbro@genmab.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic Scottsdale</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mahesh Seetharam, MD</last_name>
    </contact>
    <investigator>
      <last_name>Mahesh Seetharam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UC San Diego Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lyudmila Bazhenova, MD</last_name>
    </contact>
    <investigator>
      <last_name>Lyudmila Bazhenova, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado Cancer Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Victor Villalobos, MD</last_name>
    </contact>
    <investigator>
      <last_name>Victor Villalobos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale University, Smilow Cancer Center at Yale New Haven Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mario Sznol, MD</last_name>
    </contact>
    <investigator>
      <last_name>Mario Sznol, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Steven Attia, MD</last_name>
    </contact>
    <investigator>
      <last_name>Steven Attia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University School of Medicine, Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suresh Ramalingham, MD</last_name>
    </contact>
    <investigator>
      <last_name>Suresh Ramalingham, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mohammed Milhem, MD</last_name>
    </contact>
    <investigator>
      <last_name>Mohammed Milhem, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pasi Janne, MD</last_name>
    </contact>
    <investigator>
      <last_name>Pasi Janne, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan Comprehensive Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shirish Gadgeel, MD</last_name>
    </contact>
    <investigator>
      <last_name>Shirish Gadgeel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aaron Mansfield, MD</last_name>
    </contact>
    <investigator>
      <last_name>Aaron Mansfield, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Roswell Park Comprehensive Cancer Center</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Grace Dy, MD</last_name>
    </contact>
    <investigator>
      <last_name>Grace Dy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NYU Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luca Paoluzzi, MD</last_name>
    </contact>
    <investigator>
      <last_name>Luca Paoluzzi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Herbert Irving Comprehensive Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10034</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mathew Ingham, MD</last_name>
    </contact>
    <investigator>
      <last_name>Mathew Ingham, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke Cancer Institute</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jennifer Choe, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jennifer Choe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sujana Movva, MD</last_name>
    </contact>
    <investigator>
      <last_name>Sujana Movva, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Cancer Reearch Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Strauss, MD</last_name>
    </contact>
    <investigator>
      <last_name>James Strauss, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sarina Piha-Paul, MD</last_name>
    </contact>
    <investigator>
      <last_name>Sarina Piha-Paul, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jonathan Whisenant, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jonathan Whisenant, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Seth Pollack, MD</last_name>
    </contact>
    <investigator>
      <last_name>Seth Pollack, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Carbone Cancer Center</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ticiana Leal, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ticiana Ticiana, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuizen Leuven</name>
      <address>
        <city>Leuven</city>
        <state>Flemish Brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ignace Vergote, Professor</last_name>
    </contact>
    <investigator>
      <last_name>Ignace Vergote, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Roi Albert II - Cliniques Universitaires Saint Luc</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean Francois Baurain, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jean Francois Baurain, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Brussel - Oncologisch Centrum</name>
      <address>
        <city>Jette</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lore Decoster, MD</last_name>
    </contact>
    <investigator>
      <last_name>Lore Decoster, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medische oncologie, Oncologisch Centrum - AZ Groeninge</name>
      <address>
        <city>Kortrijk</city>
        <zip>8500</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Philip Debruyne, MD</last_name>
    </contact>
    <investigator>
      <last_name>Philip Debruyne, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.Z. Leuven Gasthuisberg, Department of General Medical Oncology</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patrick Schoffski, MD</last_name>
    </contact>
    <investigator>
      <last_name>Patrick Schoffski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Liège, Medical Oncology et. Domaine Universitaire du Sart Tilman</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guy Jerusalem, MD</last_name>
    </contact>
    <investigator>
      <last_name>Guy Jerusalem, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet, Copenhagen University Hospital</name>
      <address>
        <city>Copenhagen</city>
        <zip>DK-2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulrik Lassen, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ulrik Lassen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christian Blank, MD</last_name>
    </contact>
    <investigator>
      <last_name>Christian Blank, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Centre</name>
      <address>
        <city>Leiden</city>
        <zip>2333</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andre Johan Gelderblom, MD</last_name>
    </contact>
    <investigator>
      <last_name>Andre Johan Gelderblom, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UMC Utrecht Cancer Center</name>
      <address>
        <city>Utrecht</city>
        <zip>3584</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lotje Devriese, MD</last_name>
    </contact>
    <investigator>
      <last_name>Lotje Devriese, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universtity College London Hospitals</name>
      <address>
        <city>London</city>
        <zip>NW1 2PG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Heather Shaw, MD</last_name>
    </contact>
    <investigator>
      <last_name>Heather Shaw, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juanita Lopez, MD</last_name>
    </contact>
    <investigator>
      <last_name>Juanita Lopez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust Clinical Trials Unit</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fiona Thistlethwaite, MD</last_name>
    </contact>
    <investigator>
      <last_name>Fiona Thistlethwaite, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sir Bobby Robson Clinical Trials Unit at the Northern Centre for Cancer Care, Freeman Hospital</name>
      <address>
        <city>Newcastle</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yvette Drew, MD</last_name>
    </contact>
    <investigator>
      <last_name>Yvette Drew, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 1, 2016</study_first_submitted>
  <study_first_submitted_qc>December 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2016</study_first_posted>
  <last_update_submitted>May 4, 2018</last_update_submitted>
  <last_update_submitted_qc>May 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

